GNNSF: AI 评分 58/100 — AI 分析 (4月 2026)
Genscript Biotech Corporation is a global life science company providing research products and services. The company operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
Key Facts:
AI Score: 58/100
Sector: Healthcare
公司概况
概要：
Genscript Biotech Corporation is a global life science company providing research products and services. The company operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
Genscript Biotech Corporation is a global biotechnology company focused on life science research products and services, biologics development, industrial synthetic biology, and cell therapy. With a presence in North America, Europe, Asia Pacific, and China, Genscript serves diverse sectors, including pharmaceuticals, diagnostics, and agriculture.
GNNSF是做什么的？
Founded in 2002 and headquartered in Nanjing, China, Genscript Biotech Corporation has evolved into a key player in the life science industry. The company operates through four distinct segments. The Life Science Services and Products segment offers a range of research services, including gene synthesis, molecular cloning, and antibody development, catering to basic biology studies, pharmaceutical discovery, and disease diagnostics. The Biologics Development Services segment provides antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development for pharmaceutical, biotech, government, and academic clients. The Industrial Synthetic Biology Products segment focuses on constructing non-pathogenic microbial strains and producing industrial enzymes for the food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment is dedicated to discovering and developing chimeric antigen receptor T-cell therapies for treating liquid and solid tumors. Genscript's global presence spans North America, Europe, China, Japan, and other Asia Pacific regions, serving a diverse customer base across various industries.
GNNSF的投资论点是什么？
Genscript Biotech Corporation presents a notable market position within the biotechnology sector, driven by its diverse service offerings and global reach. Key value drivers include the continued expansion of its biologics development services and the growth of its cell therapy segment, particularly in the development of CAR-T therapies. The company's established presence in key markets like North America, Europe, and China provides a solid foundation for future growth. However, potential risks include regulatory hurdles, competition from established players, and the inherent uncertainties associated with drug development. Investors should monitor the progress of Genscript's clinical trials and its ability to maintain a competitive edge in the rapidly evolving biotechnology landscape.
GNNSF在哪个行业运营？
Genscript Biotech Corporation operates within the rapidly growing biotechnology industry, driven by increasing demand for advanced research tools, biologics development services, and cell therapies. The market is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Genscript's diverse service offerings and global presence position it to capitalize on the increasing demand for outsourced research and development services from pharmaceutical and biotechnology companies. The company's focus on cell therapy also aligns with the growing interest in personalized medicine and innovative cancer treatments.
Biotechnology
Healthcare
GNNSF有哪些增长机遇？
- Expansion of Biologics Development Services: Genscript can capitalize on the increasing demand for biologics development services by expanding its capabilities in antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development. The global biologics market is projected to reach $457 billion by 2026, presenting a significant growth opportunity for Genscript. Timeline: Ongoing.
- Growth in Cell Therapy Segment: The cell therapy market, particularly CAR-T therapies, is experiencing rapid growth due to its potential in treating liquid and solid tumors. Genscript's focus on discovering and developing CAR-T therapies positions it to benefit from this trend. The global CAR-T therapy market is expected to reach $4.9 billion by 2027. Timeline: Ongoing.
- Penetration of Industrial Synthetic Biology Products: Genscript can expand its presence in the industrial synthetic biology market by developing and producing industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The global industrial enzymes market is projected to reach $7.0 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
- Geographic Expansion: Genscript can further expand its global presence by penetrating new geographic markets, particularly in emerging economies with growing healthcare sectors. This expansion can be achieved through strategic partnerships, acquisitions, or organic growth. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Genscript can pursue strategic partnerships and acquisitions to expand its service offerings, access new technologies, and strengthen its market position. These partnerships can provide access to complementary expertise and resources, accelerating growth and innovation. Timeline: Ongoing.
- Genscript Biotech Corporation operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
- The company was founded in 2002 and is headquartered in Nanjing, China.
- Genscript Biotech Corporation has a market capitalization of $3.41 billion as of 2026-03-17.
- The company employs 5568 individuals.
- Genscript Biotech Corporation serves customers in North America, Europe, the People's Republic of China, Japan, and other Asia Pacific regions.
GNNSF提供哪些产品和服务？
- Provides gene synthesis and molecular cloning services.
- Offers oligonucleotide synthesis services.
- Specializes in protein engineering and peptide synthesis.
- Develops and produces antibody development services.
- Creates molecular diagnostics tools.
- Offers genome editing materials.
- Develops chimeric antigen receptor T-cell therapies.
GNNSF如何赚钱？
- Provides fee-for-service research and development services to pharmaceutical and biotechnology companies.
- Sells life science research products, including reagents, kits, and instruments.
- Develops and commercializes cell therapies for the treatment of cancer.
- Generates revenue through licensing agreements and royalties.
- Pharmaceutical companies
- Biotechnology companies
- Government research institutions
- Academic research institutions
- Food and chemical industries
- Proprietary technologies and intellectual property in gene synthesis and protein engineering.
- Established reputation and brand recognition in the life science research market.
- Global presence and extensive customer base.
- Integrated service offerings across multiple segments of the biotechnology industry.
什么因素可能推动GNNSF股价上涨？
- Upcoming: Progress in clinical trials for cell therapy candidates.
- Ongoing: Expansion of biologics development services.
- Ongoing: Penetration of industrial synthetic biology products.
- Ongoing: Geographic expansion into new markets.
- Ongoing: Strategic partnerships and acquisitions.
GNNSF的主要风险是什么？
- Potential: Regulatory hurdles and delays in drug approvals.
- Potential: Competition from established players in the biotechnology industry.
- Potential: Economic downturn and reduced research and development spending.
- Ongoing: Technological obsolescence and disruption.
- Ongoing: Dependence on key personnel and scientific expertise.
GNNSF的核心优势是什么？
- Diverse service offerings across multiple segments of the biotechnology industry.
- Global presence and established customer base.
- Proprietary technologies and intellectual property.
- Strong reputation and brand recognition.
GNNSF的劣势是什么？
- Reliance on outsourced research and development spending.
- Exposure to regulatory risks and uncertainties.
- Competition from established players in the biotechnology industry.
- Dependence on key personnel and scientific expertise.
GNNSF有哪些机遇？
- Expansion of biologics development services.
- Growth in cell therapy segment.
- Penetration of industrial synthetic biology products.
- Strategic partnerships and acquisitions.
GNNSF面临哪些威胁？
- Economic downturn and reduced research and development spending.
- Technological obsolescence and disruption.
- Increased competition and price pressure.
- Adverse regulatory changes and clinical trial failures.
GNNSF的竞争对手是谁？
- Unknown — Unknown — (Unknown)
Key Metrics
- MoonshotScore: 58/100
Company Profile
- CEO: Weihui Shao
- Headquarters: Nanjing, CN
- Employees: 5,568
- Founded: 2017
AI Insight
AI analysis pending for GNNSF
- OTC Tier: OTC Other
- Disclosure Status: Unknown
常见问题
What does Genscript Biotech Corporation do?
Genscript Biotech Corporation is a global biotechnology company that provides a wide array of life science research products and services. The company operates through four segments: Life Science Services and Products, which offers gene synthesis, molecular cloning, and antibody development; Biologics Development Services, which provides antibody drug discovery and cell therapy development; Industrial Synthetic Biology Products, which constructs microbial strains and produces industrial enzymes; and Cell Therapy, which focuses on developing CAR-T therapies for cancer treatment. Genscript serves pharmaceutical, biotech, government, and academic customers worldwide.
What do analysts say about GNNSF stock?
AI analysis is pending for GNNSF, so current analyst consensus is unavailable. Investors should monitor for updates on valuation metrics and growth considerations. Factors to watch include the company's progress in clinical trials, expansion of its biologics development services, and penetration of the industrial synthetic biology market. Further research is needed to assess analyst sentiment and potential investment opportunities.
What are the main risks for GNNSF?
Genscript Biotech Corporation faces several risks, including regulatory hurdles and potential delays in drug approvals, particularly for its cell therapy candidates. The company also faces intense competition from established players in the biotechnology industry. Economic downturns could reduce research and development spending, impacting Genscript's revenue. Additionally, technological advancements could lead to obsolescence of existing products and services. The company's dependence on key personnel and scientific expertise also poses a risk.